易栓症检测当前实践调查:从表型到基因型——国际血栓与止血学会科学标准化委员会通讯
国际血栓与止血学会科学标准化委员会设计问卷,调查凝血实验室易栓症检测及基因检测在诊断流程中的位置,收到82份唯一回复。调查显示实验室开展血浆表型检测,但42%限制检测申请条件,表型检测未总按已发表指南进行,基因检测未系统纳入诊断流程且多限于单变异检测,多基因 panel 仅少数实验室开展。
要点
- 82份回复显示42%实验室将血浆易栓症检测限制于血栓/止血专家申请、未抗凝患者或有强个人或家族静脉血栓史者。
- 表型检测未总按已发表指南进行,参考区间从厂商或文献转移常不理想。
- 基因检测未系统纳入诊断流程,多限于单变异检测,多基因 panel 仅少数实验室开展。
核心结论
- 调查结果强调需要就如何及何时进行此类检测提出推荐。
研究设计与样本
- 国际血栓与止血学会科学标准化委员会设计问卷,邀请所有学会成员及参加易栓症检测外部质控方案者填写,收到82份唯一回复。
主要发现
- 实验室开展血浆易栓症检测,但42%将其限制于血栓/止血专家申请、未抗凝患者或有强个人或家族静脉血栓史者。
- 表型检测未总按已发表指南进行,参考区间从厂商或文献转移常不理想。
- 结果解读时最常考虑抗凝药物使用和获得性原因。
- 基因检测未系统纳入诊断流程,多限于单变异检测,多基因 panel 检测仅少数实验室开展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnosing inherited thrombophilia as the cause of venous thromboembolism is important for patient management. Deficiencies in antithrombin, protein C, and protein S are usually diagnosed by plasma-based assays. Genetic testing can confirm the congenital nature of these deficiencies. Factor V Leiden can be detected using activated protein C resistance assays, followed by or replaced by molecular confirmation, whereas prothrombin G20210A can only be detected genetically. During the last decade, molecular techniques have evolved from single-gene sequencing to multigene sequencing panels. To understand current thrombophilia testing practices, a questionnaire was designed focusing on thrombophilia testing in coagulation laboratories and how genetic testing is placed in the diagnostic workflow. All International Society on Thrombosis and Haemostasis members and participants in external quality control schemes on thrombophilia testing were invited to complete the survey. Eighty-two unique responses were received. This international survey showed that laboratories perform plasma-based thrombophilia testing, but 42% restrict it to requests from thrombosis/hemostasis specialists, patients without anticoagulant treatment, or those with a strong personal of familial history of venous thrombosis. However, phenotypic testing is not always performed according to published guidelines. More specifically, the transference of reference intervals from manufacturers or literature is often suboptimal. For results interpretation, anticoagulant use and acquired causes were considered the most. Genetic testing is not systematically included in the diagnostic work-up algorithms and is mostly restricted to single-variant testing. Multigene panel testing is only performed by a minority of laboratories. Our results highlight the necessity for recommendations on how and when to perform this kind of testing.
引用
- Van Laer C, Moore GW, Majumder R, et al. Survey on current practice in thrombophilia testing: from phenotype to genotype. Communication from the SSC of the ISTH. J Thromb Haemost. 2025. PMID: 41238194. doi:10.1016/j.jtha.2025.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。